Crizotinib CAS 877399-52-5 Intende ≥99.0% API Factory High Quality
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica Crizotinib (CAS: 877399-52-5) cum qualitate alta.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Crizotinib,Please contact: alvin@ruifuchem.com
| Nomen chemicum | Crizotinib |
| Synonyma | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazolum-4-yl)-pyridinum-2-ylamine;(R) -3-[1-(2,6-Dichloro-3-Fluorophenyl) ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazolum-4-yl)pyridinum-2-ylamine |
| CAS Number | 877399-52-5 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C21H22Cl2FN5O |
| M. Pondus | 450.34 |
| Liquescens punctum | 192℃ |
| Density | 1.47±0.10 g/cm3 |
| Repono Temperature | Locus temperatus |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White pulveris |
| Lepidium sativum | Per IR, HPLC |
| Solutio in claritate | Conformare ad Latin |
| Damnum in Siccatio | ≤1.00% |
| Residere in Ignition | ≤0.50% |
| Related immunditias | (per HPLC) |
| una immunditia | ≤0.50% |
| Totalis immunditias | ≤1.00% |
| Metalla gravis | ≤20ppm |
| Assay | ≥99.0% |
| RELICTUM Solvents | Occursum Specification |
| Fasciae vita | XXIV Menses |
| Test Standard | Enterprise Standard |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Salutis descriptio 24/25 - contactus cum cute et oculis fuge.
UN IDs UN 3077 9 / PGIII
WGK Germania 3
HS Code 2933900099
Aleam Class INRITANT
Crizotinib ( CAS 877399-52-5) , (Crizotinib, Xalkori R), est potens et selectiva ATP inhibitoris minoris inhibitoris moleculi concursus in ALK et c-Met.Mense Augusto MMXI, Civitatibus Foederatis Americae FDA Crizotinib approbata est ad curationem lymphoma kinasis anaplasticae (ALK) ordinatae cancri pulmonis non parvae cellae (NSCLC).Crizotinib est duplex ATP auctor inhibitor kinasium tyrosinae c-MET (Mesenchymal-epithelialis Transitionis Factor) kinasus (cellularis IC50=8 nM) et ALK (cellularis IC50=20 nM), quorum utrumque magni ponderis scuta pro chemotherapy cancro sunt.Cum crizotinib probatum est propter selectivity versus alias kinases inventas enzyme IC50 habere intra 100-duplices multiplices c-MET pro 13 ex 120 kinasibus probatis.In cellulis pertentationibus crizotinib inventa est RON (recepteur d'origine nantais) kinase cum 10 duplici fenestra selectivity super c-MET.
Crizotinib (PF-02341066) Crizotinib inhibitor potens c-Met et ALK, valores IC50 in cellam primordium erant 11 nM et 24 nM, respective.Inhibitor etiam potentis ROS1 cum valore Ki minoris quam 0.025 nM est.Crizotinib autophagiam inducere potest in variis lineis cancri pulmonis pulmonis, per iter STAT3 inhibito.
Crizotinib est potens et selectivus dualis inhibitor factoris transitus mesenchymal-epithelialis (c-MET) kinasi et lymphoma kinasi anaplastici (ALK).Crizotinib est agens potentiale antitumor.Mense Augusto MMXI, Civitatibus Foederatis Americae FDA crizotinib approbata ad curationem lymphoma kinasis anaplasticae (ALK) ordinatae, cancer pulmonis non parvae cellae (NSCLC).
Crizotinib (Xalkori(R), Pfizer) anno 2011 probatus, primus probatus inhibitor lymphoma kinasi anaplasticae (ALK).ROS protooncogene 1-encoded kinase (ROS1) tyrosini kinasi insulin receptoris classis et MET proto-oncogene-encoded kinase hepatocytae augmenti receptoris (HGFR) sunt aliae kinases iaculatae a crizotinib. Cum probatus anno 2011, crizotinib primus fuit. medicamento specie NSCLC aegros targeting.Autem, resistentia crizotinib observata esse solet in applicatione initiali circa 8 menses et plus quam dimidium aegroti a crizotinib-tractatis effectus gastrointestinales experti sunt.Anno 2016, crizotinib etiam pro ROS1 positivo NSCLC a FDA probatus est.
Crizotinib (Xalkori) receptor oralis inhibitoris tyrosini kinasi significatus est ad curationem aegrorum progressorum vel metastaticorum cellulae non-parvae pulmonis cancri (NSCLC).Communis latus effectus cum Xalkori usu includunt infectio respiratoriae superioris, nausea, vomitus, dolor stomachi, appetitus decrescentes, insomnia, vertigo, lassitudo animi, fluxus ventris, constipatio, temerarius vel pruritus, frigus symptomata (turba nasi, sternutatio, faucium), torpor vel medullis aut tumor in manibus aut pedibus.
